In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis

• Published in: Microbiology spectrum 2023-10, Vol.11 (5), p.e0462722-e0462722
• Main Authors: An, Huiru, Sun, Wenna, Liu, Xiao, Wang, Tianhao, Qiao, Juan, Liang, Jianqin
• Format: Article
• Language: English
• Subjects: contezolid; drug resistant; in vitro; Mycobacterium tuberculosis; Observation
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.04627-22

A novel oxazolidinone for the treatment of Mycobacterium tuberculosis has been developed, but the activity of contezolid (MRX-I) still needs to be clarified. In this study, we isolated Mycobacterium tuberculosis from 48 clinical patients with pulmonary tuberculosis. Roche drug susceptibility tests identified drug-sensitive and 39 drug-resistant M. tuberculosis isolates. Drug susceptibility assays indicated that MRX-I exhibited anti- Mycobacterium tuberculosis activity against both drug-sensitive and drug-resistant isolates, with an advantage against drug-resistant isolates. The results also showed that the anti- Mycobacterium tuberculosis activity was comparable to that of linezolid. Currently, Mycobacterium tuberculosis has exhibited increased drug resistance, leading to ineffective drug treatment in many patients with tuberculosis. Among the anti- Mycobacterium tuberculosis drugs, oxazolidinones have been gradually developed. Contezolid (MRX-I) has been newly developed in China with advantages versus the first oxazolidinone antibiotic approved by the Food and Drug Administration for clinical use, but the anti- M. tuberculosis activity needs to be further clarified. In this study, in vitro activities of MRX-I against M. tuberculosis were tested. The drug susceptibility assays indicated that MRX-I exhibited anti- M. tuberculosis activity comparable to that of linezolid, with an advantage against drug-resistant isolates.